Akros Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Akros Pharma sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Akros Pharma: 18 sponsored US clinical trials, none currently recruiting.
Akros Pharma sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anemia in Chronic Kidney Disease, with 1 trials.
Top-decile sponsor footprint
Akros Pharma ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
NCT06017609
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
NCT04465877
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03832738
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03358290
Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
NCT02919475
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
NCT02805244
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
NCT02581124
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252
NCT02120976
Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
NCT02106585
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
NCT01978587
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
NCT01971164
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
NCT01699737
Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects
NCT01473069
Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects
NCT01475981
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
NCT00997152
Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
NCT00929539
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
NCT00748852
Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels
NCT00749788
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 9 |
Therapeutic Areas
How the Akros Pharma early-phase archive is shaped
18 indexed studies, none listed as recruiting (0% open); 13 completed (72%).
Phase mix: 0 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Anemia in Chronic Kidney Disease (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Akros Pharma: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Akros Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
- Beckman Coulter · 18 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Akros Pharma page
18 registered trials is a research-attention snapshot, not an endorsement of Akros Pharma or any single study.
- None of Akros Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Anemia in Chronic Kidney Disease is the condition Akros Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anemia in Chronic Kidney Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Akros Pharma pipeline card: 18 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.